Niacin-ligated platinum(iv)–ruthenium(ii) chimeric complexes synergistically suppress tumor metastasis and growth with potentially reduced toxicity in vivo. Issue 20 (12th February 2020)

• Record Type: Journal Article
• Authors: Shu, Liwei; Ren, Lulu; Wang, Yuchen; Fang, Tao; Ye, Zhijian; Han, Weidong; Chen, Chao; Wang, Hangxiang
• Is Part Of: Chemical communications. Volume 56:Issue 20(2020)
• Page Start: 3069
• Page End: 3072
• Publication Date: 2020-02-12
• Subjects: Chemistry -- Periodicals; 540
• DOI: 10.1039/c9cc09016a
• Languages: English
• ISSNs: 1359-7345

Abstract

Abstract : The chimeric Pt(iv )–Ru(ii ) complex was designed to simultaneously release cytotoxic cisplatin and an antimetastatic Ru(ii )–arene compound, thereby producing potent anticancer activity with high drug tolerability in animals. Abstract : Niacin-ligated platinum(iv )–ruthenium(ii ) chimeric complexes (PtRu 1–4 ) have been synthesized and evaluated for their antitumor performance. Using the optimal complex, PtRu-1, we show that this water-soluble chimeric prodrug not only potently inhibits the metastasis and proliferation of tumor cells but also has an unexpectedly higher safety margin in animals compared with the traditionally-used, clinically approved drug cisplatin.